Flu vaccine trial postponed

Published: 24/09/2009 at 10:41 AM
Online news: Breakingnews

The Public Health Ministry has decided to postpone the trial of flu vaccine on human for another two weeks because it does not want to rush the process when it is not ready, Public Health Minister Witthaya Kaewparadai said on Thursday.

The trial will be conducted on Oct 6, he said.

The decision was made after the Government Pharmaceutical Organisation met with officials in charge of producing the H1N1 vaccine. Both sides want more information on the trials conducted in Russia, the equipments used in the experiments and more, he added.

The team does not want to conduct the trial in haste because it wants the public to be confident with the trial and the vaccine, the minister said.

On Wednesday, health authorities were considering shelving plans to order an added 3 million flu vaccine doese to cover priority groups because of global production shortages.

About the author

Writer: BangkokPost.com

Keep this article in your social bookmark:

Latest stories in this category:

Share your thoughts

For more candid, lengthy, conversational and open discussion between one another, use our Forum

Report objectionable comments click here. Include: discussion #, commenter name, comment date / time as it looks on the page. Example: discussion 15: 09/01/2009 at 10:00 AM.

Stense

Discussion 3 : 24/09/2009 at 11:58 AM3
What happened to the stock of NASAL SPRAY? Shiped for free to "Zimbabwe"! How much did the GOV pay to the "laboratory,"and who got the corrupt money?
wow google Baxter

Discussion 2 : 24/09/2009 at 11:55 AM2
Baxter Vaccine Patent Application US 2009/0060950 A1 says:

'... In particular preferred embodiments the composition or vaccine comprises more than one antigen ... such as influenza A and influenza B in particular selected from of one or more of the human H1N1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3, H10N7 subtypes, of the pig flu H1N1, H1N2, H3N1 and H3N2 subtypes, of the dog or horse flu H7N7, H3N8 subtypes or of the avian H5N1, H7N2, H1N7, H7N3, H13N6, H5N9, H11N6, H3N8, H9N2, H5N2, H4N8, H10N7, H2N2, H8N4, H14N5, H6N5, H12N5 subtypes.'

The patent was published in March 2009, a month before the virus was released in Mexico in April, but it was filed seven months before this 'new strain' was officially known about. It is the most blatant set-up you could ever see.

The patent includes the following ingredients and toxicity warning:

'Suitable adjuvants can be selected from mineral gels, aluminium hydroxide, surface active substances, lysolecithin, pluronic polyols, polyanions or oil emulsions such as water in oil or oil in water, or a combination thereof. Of course, the selection of the adjuvant depends on the intended use. E.g. toxicity may depend on the destined subject organism and can vary from no toxicity to high toxicity.'

Nice.
Not for me Thanks

Discussion 1 : 24/09/2009 at 11:37 AM1
A U.S. based pharmaceutical company that just weeks ago was involved in a scandal involving vaccines tainted with deadly avian flu virus has been chosen to head up efforts to produce a vaccine for the Mexican swine flu that has seemingly migrated into the U.S. and Europe.
Baxter confirmed over the weekend that it is working with the World Health Organization on a potential vaccine to curb the deadly swine flu virus that is blamed for scores of deaths in Mexico and has emerged as a threat in the U.S., reports the Chicago Tribune.
Baxter has previously worked with governments all over the globe to develop and produce vaccines to protect against infectious disease or potential threats from bioterrorism. After 9/11 Baxter helped supply stockpiles of a smallpox vaccine and in 2003 the company was contracted to develop a vaccine to combat the SARS virus. In 2006 the UK Government announced plans designed to inoculate every person in the country with Baxter’s vaccines in the event of a flu pandemic.
However, Baxter has a very recent and most disturbing connection to flu vaccines.
As reported by multiple sources last month, including the Times of India, vaccines contaminated with deadly live H5N1 avian flu virus were distributed to 18 countries last December by a lab at an Austrian branch of Baxter.
It was only by providence that the batch was first tested on ferrets in the Czech Republic, before being shipped out for injection into humans. The ferrets all died and the shocking discovery was made.

Flu vaccine trial postponed